



Zetiq to present at CHI's Early Oncology Partnering Forum February 21, 2011 (San Francisco, USA)

Zetiq Technologies Ltd. ("Zetiq"), a subsidiary of Bio-Light Ltd. (TASE: BOLT) and a developer of early cancer diagnosis tools, announces that it will be presenting its technology at the Early Oncology partnering forum to be held in San Francisco on February 21, 2011.

"The Early Oncology Partnering Forum meeting is part of the CHI's Molecular Medicine Tri-Conference 2011 event. This important event brings together leading companies, business and scientific leaders in the field of cancer diagnosis. The selection of Zetiq as one of the companies to present at this prestigious event is a great opportunity for us to update the industry in the important progress we have made", said Dr. Adi Elkeles, Zetiq CEO.

About Zetiq:

Zetiq Technologies Ltd. develops effective cancer diagnostic tools. A significant medical need exists for early stage diagnostic tools for screening, monitoring or diagnosing cancer. Zetiq offers unique advantages in this market with its proprietary CellDetect® technology for differential staining and morphological visualization to differentiate between non cancer cells and a wide variety of cancer indications. The Company's products alleviate the process of locating and identifying suspected cancer cells, reduce error, simplify the process and have a potential to be fully automated.

Zetiq is a subsidiary of Bio-Light Life Science Investments, a management and holding company specializing in biomedical technologies. Bio-Light is traded on the Tel Aviv Stock Exchange under the symbol TASE: BOLT.

For further information please contact:

Dr. Adi Elkeles

CEO

Zetiq Technologies Ltd.

www.zetiq.co.il

adi@bio-light.co.il